A phase 3, multicenter, randomized, double-blind, placebo-controlled, active reference (Adalimumab) study evaluating the efficacy and safety of Bimekizumab in the treatment of subjects with active psoriatic arthritis

Project: Research

Project Details

StatusActive
Effective start/end date19/12/1918/12/24

Keywords

  • clinical trial
  • treatment efficacy
  • psoriatic arthritis
  • treatment safety